Vanda Pharmaceuticals Inc. (VNDA) stock
VNDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3055% below fair value
$3.75−0.06 (-1.57%)
Close on Nov 18, 2026Market cap $226.76MP/E –Yield –
Vanda Pharmaceuticals cash
Cash and short-term investments held at the end of each period.
Vanda Pharmaceuticals's cash was $61.93M at Sep 30, 2026. For fiscal 2025 it was $84.85M, down 17.4% from the year before. Over ten years it grew -5.1% a year on average. The highest annual figure on record is $433.33M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $84.85M | -17.4% |
| FY2024 | Dec 31, 2024 | $102.79M | -24.6% |
| FY2023 | Dec 31, 2023 | $136.29M | +0.6% |
| FY2022 | Dec 31, 2022 | $135.50M | -68.7% |
| FY2021 | Dec 31, 2021 | $433.33M | +17.7% |
| FY2020 | Dec 31, 2020 | $368.32M | +17.8% |
| FY2019 | Dec 31, 2019 | $312.71M | +21.2% |
| FY2018 | Dec 31, 2018 | $258.10M | +79.1% |
| FY2017 | Dec 31, 2017 | $144.12M | +1.4% |
| FY2016 | Dec 31, 2016 | $142.17M | -1.2% |
| FY2015 | Dec 31, 2015 | $143.97M | +10.9% |
| FY2014 | Dec 31, 2014 | $129.82M | -0.4% |
| FY2013 | Dec 31, 2013 | $130.35M | +8.3% |
| FY2012 | Dec 31, 2012 | $120.40M | -19.1% |
| FY2011 | Dec 31, 2011 | $148.88M | -24.8% |
| FY2010 | Dec 31, 2010 | $198.04M | -3.5% |
| FY2009 | Dec 31, 2009 | $205.30M | +425.3% |
| FY2008 | Dec 31, 2008 | $39.08M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $61.93M | -11.6% |
| Q2 FY2026 | Jun 30, 2026 | $55.88M | -31.0% |
| Q1 FY2026 | Mar 31, 2026 | $54.03M | -51.7% |
| Q4 FY2025 | Dec 31, 2025 | $84.85M | -17.4% |
| Q3 FY2025 | Sep 30, 2025 | $70.02M | -30.3% |
| Q2 FY2025 | Jun 30, 2025 | $80.98M | -21.3% |
| Q1 FY2025 | Mar 31, 2025 | $111.80M | -10.7% |
| Q4 FY2024 | Dec 31, 2024 | $102.79M | -24.6% |
| Q3 FY2024 | Sep 30, 2024 | $100.50M | -45.1% |
| Q2 FY2024 | Jun 30, 2024 | $102.95M | -31.4% |
| Q1 FY2024 | Mar 31, 2024 | $125.16M | -64.7% |
| Q4 FY2023 | Dec 31, 2023 | $136.29M | +0.6% |
| Q3 FY2023 | Sep 30, 2023 | $183.19M | +270.8% |
| Q2 FY2023 | Jun 30, 2023 | $150.03M | -66.0% |
| Q1 FY2023 | Mar 31, 2023 | $354.17M | -18.6% |
| Q4 FY2022 | Dec 31, 2022 | $135.50M | -68.7% |
| Q3 FY2022 | Sep 30, 2022 | $49.40M | -87.8% |
| Q2 FY2022 | Jun 30, 2022 | $440.86M | +11.2% |
| Q1 FY2022 | Mar 31, 2022 | $435.18M | +15.1% |
| Q4 FY2021 | Dec 31, 2021 | $433.33M | +17.7% |
| Q3 FY2021 | Sep 30, 2021 | $405.97M | +16.5% |
| Q2 FY2021 | Jun 30, 2021 | $396.49M | +16.7% |
| Q1 FY2021 | Mar 31, 2021 | $378.16M | +21.1% |
| Q4 FY2020 | Dec 31, 2020 | $368.32M | +17.8% |
| Q3 FY2020 | Sep 30, 2020 | $348.55M | +46.6% |
| Q2 FY2020 | Jun 30, 2020 | $339.85M | +21.3% |
| Q1 FY2020 | Mar 31, 2020 | $312.33M | +16.6% |
| Q4 FY2019 | Dec 31, 2019 | $312.71M | +21.2% |
| Q3 FY2019 | Sep 30, 2019 | $237.79M | -1.2% |
| Q2 FY2019 | Jun 30, 2019 | $280.16M | +21.2% |
| Q1 FY2019 | Mar 31, 2019 | $267.84M | +7.6% |
| Q4 FY2018 | Dec 31, 2018 | $258.10M | +79.1% |
| Q3 FY2018 | Sep 30, 2018 | $240.58M | +71.0% |
| Q2 FY2018 | Jun 30, 2018 | $231.22M | +67.6% |
| Q1 FY2018 | Mar 31, 2018 | $248.83M | +79.6% |
| Q4 FY2017 | Dec 31, 2017 | $144.12M | +1.4% |
| Q3 FY2017 | Sep 30, 2017 | $140.71M | – |
| Q2 FY2017 | Jun 30, 2017 | $137.95M | – |
| Q1 FY2017 | Mar 31, 2017 | $138.59M | – |
| Q4 FY2016 | Dec 31, 2016 | $142.17M | – |
See a number that looks wrong?